Do patients enrolled in clinical trials really represent the acute myeloid leukemia population?

During the 63rd ASH Annual Meeting and Exposition, Know AML spoke with Mycal Casey, Augusta University, Augusta, US. We asked, Do patients enrolled in clinical trials really represent the acute myeloid leukemia population?

Casey begins by discussing underrepresentation of Hispanic and African American populations as well as women in clinical trials. He goes on to outline the impact of mortality on clinical trials that lead to drug approval and global disparities in trial populations. Finally, Casey makes 3 suggestions that could improve the applicability of data and representation in clinical trials.